Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Gilead Sciences, Inc.
< Previous
1
2
3
4
5
6
7
8
9
Next >
U.S. FDA Approves Trodelvy® in Pre-treated HR+/HER2- Metastatic Breast Cancer
February 03, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences Announces 2.7 Percent Increase in First Quarter 2023 Dividend
February 02, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences Announces Fourth Quarter and Full Year 2022 Financial Results
February 02, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Awards $7.6 Million in Grants to Advance Health Equity in Breast Cancer
February 01, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences to Present at Upcoming Investor Conferences
January 27, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences to Release Fourth Quarter & Full Year 2022 Financial Results on Thursday, February 2, 2023
January 19, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
European Medicines Agency Validates Marketing Authorization Application For Trodelvy® (sacituzumab govitecan-hziy) For Pre-treated HR+/HER2- Metastatic Breast Cancer
January 03, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead and EVOQ Therapeutics Announce Collaboration to Advance Immunotherapies
January 03, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics
December 27, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
JNCE
Gilead Sciences to Present at Upcoming Investor Conference
December 23, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Yescarta® Now Approved in Japan for Initial Treatment of Relapsed/Refractory Large B-Cell Lymphoma
December 22, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV
December 22, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Kite to Acquire Tmunity Therapeutics to Pursue Next Generation CAR T-Cell Therapy Advancements in Cancer
December 20, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences Again Named to Dow Jones Sustainability World Index
December 12, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
New Analyses of Kite's Tecartus® CAR T-Cell Therapy Provide Additional Evidence Supporting Overall Survival and Durability of Response
December 12, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Three-Year Follow-Up Analysis of Kite’s Yescarta® CAR T-cell Therapy (ZUMA-5 Trial) - 52% of Patients With Indolent Lymphomas Continued to Have Ongoing Responses at a Median Follow-Up of 40.5 Months
December 12, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Body of Evidence Grows From ZUMA-7 Study Supporting Initial Treatment With Kite’s Yescarta® CAR T-cell Therapy for Patients With Relapsed or Refractory Large B-cell Lymphoma
December 11, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Time to CAR T-cell Therapy May Impact Outcomes for Patients With Relapsed/Refractory Large B-cell Lymphoma in New CIBMTR Analysis
December 11, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
December 09, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
ACLX
GILD
Kite and Daiichi Sankyo Announce Changes to YESCARTA® CAR T-Cell Therapy Licensing Agreement in Japan
December 07, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
New Data for Trodelvy Demonstrate Clinical Efficacy Across Trop-2 Expression Levels in HR+/HER2- Metastatic Breast Cancer
December 06, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
European Commission Grants Expanded Marketing Authorization for Gilead’s Biktarvy® for the Treatment of HIV in Pediatric Populations
November 29, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences to Present at Upcoming Investor Conferences
November 15, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead and Kite Oncology Demonstrate Transformative Impact of Cell Therapy and Promise of Blood Cancer Portfolio at ASH 2022
November 03, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
U.S. Food and Drug Administration Approves Vemlidy® (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients
November 02, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead to Present Data Across Viral Hepatitis and Liver Fibrosis at The Liver Meeting® 2022, Reinforcing Gilead as a Leader in Addressing Treatment Needs for People Living With Liver Disease
November 01, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Sciences Announces Third Quarter 2022 Financial Results
October 27, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Presents Real-World Evidence Reinforcing the Use of Biktarvy® for the Treatment of People Living With HIV With a Range of Comorbidities
October 24, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Kite and Refuge Biotechnologies Announce Exclusive License Agreement for Investigational Gene Expression Platform for Blood Cancers
October 20, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
Gilead Presents Real-World and Long-Term Data From HIV Research Programs at HIV Glasgow 2022
October 18, 2022
From
Gilead Sciences, Inc.
Via
Business Wire
Tickers
GILD
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.